- Open Access
Evaluation of onchocerciasis seroprevalence in Bioko Island (Equatorial Guinea) after years of disease control programmes
Parasites & Vectors volume 9, Article number: 509 (2016)
Onchocerciasis or “river blindness” is a chronic parasitic disease caused by the filarial worm Onchocerca volvulus, transmitted through infected blackflies (Simulium spp.). Bioko Island (Equatorial Guinea) used to show a high endemicity for onchocerciasis. During the last years, the disease control programmes using different larvicides and ivermectin administration have considerably reduced the prevalence and intensity of infection. Based on this new epidemiological scenario, in the present work we aimed to assess the impact of the strategies applied against onchocerciasis in Bioko Island by an evaluation of IgG4 antibodies specific for recombinant Ov-16 in ELISA.
A cross-sectional study was conducted in Bioko Island from mid-January to mid-February, 2014. Twenty communities were randomly selected from rural and urban settings. A total of 140 households were chosen. In every selected household, all individuals aged 5 years and above were recruited; 544 study participants agreed to be part of this work. No previous data on onchocerciasis seroprevalence in the selected communities were available. Blood samples were collected and used in an “ELISA in-house” prepared with recombinant Ov-16, expressed and further purified. IgG4 antibodies specific for recombinant Ov-16 were evaluated by ELISA in all of the participants.
Based on the Ov-16 ELISA, the onchocerciasis seroprevalence was 7.9 %, mainly concentrated in rural settings; samples from community Catedral Ela Nguema (# 16) were missed during the field work. Among the rural setups, communities Inasa Maule (# 7), Ruiché (# 20) and Barrios Adyacentes Riaba (# 14), had the highest seropositivity percentages (29.2, 26.9 and 23.8 %, respectively). With respect to the urban settings, we did not find any positive case in communities Manzana Casa Bola (# 3), Colas Sesgas (# 6), Getesa (# 8), Moka Bioko (# 9), Impecsa (# 10), Baney Zona Baja (# 12) and Santo Tomás de Aquino (# 1). No onchocerciasis seropositive samples were found in 10-year-old individuals or younger. The IgG4 positive titles increased in older participants.
A significant decline in onchocerciasis prevalence was observed in Bioko Island after years of disease-vector control and CDTI strategy. The seroprevalence increased with age, mainly in rural settings that could be due to previous exposure of population to the filarial parasite, eliminated by the control programmes introduced against onchocerciasis. A new Ov-16 serological evaluation with a larger sample size of children below 10 years of age is required to demonstrate the interruption of transmission of O. volvulus in the human population of Bioko Island (Equatorial Guinea) according to the WHO criteria.
Onchocerciasis or “river blindness” is a chronic parasitic disease caused by the filarial worm Onchocerca volvulus. It is transmitted through the repeated bites of infected blackflies (Simulium spp.) from human to human. In the human body, the larvae form nodules in the subcutaneous tissue, where they mature to adult worms. After mating, the female adult worm release microfilariae (MF) that move through the body. When MF die they cause a variety of pathological conditions, affecting principally eyes and skin .
In 1974, the onchocerciasis control programme (OCP) was launched in the African continent, with the aim of eliminating the vector blackfly by regular aerial larviciding. This strategy was encouraged by the decision taken by Merck in 1987 to make ivermectin (Mectizan) available free of charge through the Mectizan Donation Programme (MDP) . Later on, in 1995, the African Programme for Onchocerciais Control (APOC) begun annual administration of the community-directed treatment with ivermectin (CDTI) [3, 4]. APOC based the drug administration on the previous assessment of the local disease endemicity by rapid epidemiological mapping of onchocerciasis (REMO) . All these interventions have demonstrated efficacy in controlling onchocerciasis as a public health problem in Africa .
Bioko Island, located in Equatorial Guinea, used to show a high endemicity for onchocerciasis [7, 8]. The introduction of the disease control programmes, mentioned above, allowed the reduction in the prevalence and intensity of infection , and the presumptive elimination of the onchocerciasis vector, the Bioko form of Simulium yahense . The CDTI has been continued until now. At this stage, surveillance and evaluation activities are especially necessary to verify that the parasite transmission has been interrupted . Onchocerciasis detection has been traditionally carried out by nodule palpation and microscopic examination of MF in skin snips, although nodule palpation has poor diagnostic precision and morphological MF identification requires substantial expertise, is time-consuming and shows poor sensitivity . In locations where onchocerciasis prevalence has dropped down thanks to CDTI, and disease elimination needs to be evaluated, new survey and diagnostic tools are required. Therefore, innovative strategies for onchocerciasis accurate diagnosis, immunological and DNA-molecular approaches, have been developed during the last decades [13–15].
Within immunodiagnosis options, the evaluation of IgG4 responses to the Ov-16 antigen, by ELISA and/or rapid-format card test, has emerged as an alternative tool to determine the impact of the disease elimination progress [16, 17]. Onchocerca volvulus-Ov-16 antigen belongs to the phosphatidylethanolamine-binding protein family (A.N.: P31729 [18, 19]), and expressed as a recombinant antigen allowed the early and specific detection of new Onchocerca infections in children, with good sensitivity . WHO has been using the Ov-16/IgG4 system to verify the interruption of transmission of human onchocerciasis, besides ophthalmological and/or entomological assessments, since 2001 . This serological approach has been employed, among others, to certify the transmission suppression of onchocerciasis in the Americas [21–23] and in some African endemic regions [4, 24, 25], and again it has been recently recommended by WHO in the last onchocerciasis guidelines .
The present work represents a preliminary study, which aimed to assess the impact of CDTI strategy on onchocerciasis control in Bioko Island by the evaluation of IgG4 antibodies specific for recombinant Ov-16 by using ELISA .
The study took place in Bioko Island from mid-January to mid-February, 2014. The Island is a part of the Republic of Equatorial Guinea, which also includes Rio Muni on the mainland and the island of Annobon. Bioko Island comprises two zones: Bioko Norte (Malabo, Baney and Rebola districts) and Bioko Sur (Luba and Riaba districts). It is located in the Bay of Guinea in Central Africa, about 40 km southwest of the Cameroon coast. The surface area of Bioko Island is of approximately 2017 km2 and it is about 72 km in length. Most of the 260,000 inhabitants live in the capital, Malabo.
The island has a humid tropical climate. Mean daily maximum and minimum temperatures range between 29–32 °C and 19–22 °C, respectively. The rainfall is highly seasonal, with a dry season which lasts from December to April; many of the rivers and streams dry up soon after the end of the rainy season. Before the elimination of the vector blackfly, the levels of vector biting were lowest during January to April coinciding with the dry season reduction in suitable breeding sites . Currently, seasonality and rainfall are not expected to influence the transmission of O. volvulus, as there is no evidence of vector re-emergence in the island since 2005.
Study design, sample size and sampling technique
A cross-sectional study was conducted. Sampling was carried out by multistage cluster survey. The sample size was computed using Epi-Info version 3.4.1 free software considering the following parameters: hypothesized prevalence of 10 % and a standard error of 2 %. We assumed a design effect of 2, corresponding to the complex design. The initial sample size was 450. It was increased (+20 %) in prevision of missing data. The equation used is included below: n = DEFF p (1-p)/e^2, where DEFF is the design effect, e is the desired standard error and p is the prevalence.
First, 20 communities were randomly selected with probability proportional to size (Fig. 1). Secondly, sampling units were randomly selected households from an updated census from each community, provided by the head of the village (in rural areas) or neighbourhood (in urban zones). In every selected household, all individuals over 5 years of age who had permanently lived in Bioko Island during the last 5 years were recruited. People who were born outside Equatorial Guinea were excluded.
A closed-ended structured questionnaire was administered to every study participant by trained medical personnel. The questionnaire comprised socio-demographic and clinical information and was pre-tested on close areas not included in this study for clarity and cultural acceptability. Each interview was made by house-to-house visit. If the study participant was less than 15 years of age, the questionnaire was answered by a parent or guardian. Those children under 5 years of age, no Equatoguinean nationality, and/or who had changed residence in the last 5 years were excluded.
The coordinates (longitude and latitude) of every selected household were also recorded on-site using Dakota™10 Garmin single handheld GPS receivers.
Three skin snips specimens were collected from every participant (two from right iliac crest, one from left iliac crest). No special collection time was considered as the microfilariae of O. volvulus are non-periodic. Two samples were immersed in normal saline solution to prevent the preparation from drying out and sent to the local hospital laboratory to be read under a microscope (magnification of 100×) after 24 h. Results were expressed for each individual as ‘positive’ or ‘negative’. Laboratory results were recorded on the original (field) registration form.
Blood drops were taken from peripheral blood samples that were collected from each individual  and placed on a label circle of Whatman No. 2 filter paper (Milipore). Filter paper blood samples were dried, individually wrapped in plastic bags with a silica desiccant and stored in coolers at 4 °C until they could be transferred to a refrigerator, where they were stored until further analysis.
Production of Ov-16 recombinant antigen
The Ov-16 nucleotide sequence , without the signal peptide, was amplified by PCR from a recombinant pMAL-Ov-16 plasmid, kindly donated by Professor JE Bradley, School of Life Sciences and University of Nottingham, UK. A poly-His tail was added to the carboxy-terminus of the amplified Ov-16 sequence, which was then subcloned into pGEX-6P-1 plasmid (GE Healthcare, Little Chalfont, UK), a glutathione S-transferase fusion vector. The GST-Ov-16 recombinant protein was purified by Glutathione Sepharose 4B affinity chromatography (GE Healthcare) according to the manufacturer’s recommendations. Later, separation of the recombinant protein from the glutathione S-transferase moiety was accomplished by site-specific proteolysis using PreScissionTM Protease reaction (GE Healthcare). After dialyzing against PBS, the Ov-16-His recombinant protein was repurified by Ni2+ Sepharose 4B affinity chromatography (GE Healthcare) according to the manufacturer’s recommendations. Finally, the Ov-16-His was again dialyzed against PBS and quantified with Pierce™ BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA).
In-house ELISA test
In the laboratory, serum samples were eluted from Whatman filter paper as follows. Four 3 mm-punches of blood saturated filter paper were placed in 200 μl of dilution buffer (phosphate-buffered saline (PBS)-Tween 20 0.05 %-skim milk 3 %) and eluted overnight at 4 °C, according to Lindblade et al.  with small modifications.
The serum elution was run in duplicate in a standard enzyme-linked immunosorbent assay (ELISA) to detect IgG4 antibodies against the Ov-16 recombinant antigen essentially as previously described . Briefly, 96-well polystyrene plates (Nunc MaxiSorp® flat-bottom 96 well plate) were sensitized with the purified Ov-16 recombinant protein (0.5 μg/ml; 100 μl/well) in carbonate buffer pH 9.6, overnight at 4 °C. Later, the plates were washed three times with phosphate PBS, pH 7.4 plus 0.05 % Tween 20 (PBST, washing buffer) and blocked in dilution buffer (PBST plus 0.3 % skim milk) for 1 h at 37 °C. After blocking, plates were washed 3 times as described above. The diluted serum samples (100 μl) were added in duplicate to the corresponding wells; eluted positive and negative controls, equally processed and diluted, were also introduced. After 1 h of incubation at 37 °C, the plates were PBST-washed 5 times and bound antibodies were detected by exposure to horseradish peroxidase conjugated mouse anti-human IgG4 (Southern Biotech, Birmingham, AL, USA), 1/4000 in PBST; the plates were incubated and washed as described above. The substrate buffer was prepared with an ABTS tablet (2,2′-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt; Sigma-Aldrich, A9941, Saint Louis, MO, USA) plus 20 ml of phosphate-citrate buffer with sodium perborate (Sigma-Aldrich P4922); 100 μl of substrate buffer was added to each well and then the plate was incubated at 37 °C in darkness. The plates were read at 405 nm with a 620 nm reference filter when the 1/8 positive control dilution was around 0.5 OD (see below).
We used a standard curve on each plate to identify positive samples and permit comparisons between plates and over days, as previously described [25, 29]. The standard curve was prepared using a positive onchocerciasis sample, obtained from an onchocerciasis patient confirmed by both clinical manifestations and parasitological diagnosis; the standard curve dilutions (1/8; 1/16; 1/32; 1/64; 1/128) were prepared through elution of the blood sample placed on a Whatman filter paper. Each of these dilutions was assigned the arbitrary units shown in Table 1. The cut-off was determined after analyzing 83 negative samples from sub-Saharan (n = 33) /Spanish/Latin American individuals and 5 positive samples (parasitologically and clinically confirmed as O. volvulus-positive individuals). The cut-off was set at 40 arbitrary units corresponding to the 1/64 dilution by identifying the value that optimized both sensitivity and specificity.
Positive onchocerciasis samples by ELISA-Ov-16/IgG4 were re-tested in a rapid format for the detection of IgG4 antibodies against Ov-16 recombinant antigen (SD Onchocerciasis IgG4-Bioline, Standard Diagnostics, Inc., Gyeonggi, South Korea); the procedure shows a sensitivity of 81.1 % and a specificity of 99.0 % according to the manufacturer. The immunochromatographic tests were developed following the manufacturer’s recommendations, using 10 μl blood samples. We considered a sample as positive when it was possible to see a red line on the test line even when the line was very weak.
The collected data were double entered into a data entry file using EpiData software, V.3.1. Frequencies, means and standard deviations (SD) were computed to summarize the data. Antibody prevalence was defined as the proportion of positive results among subjects who had definite results for the Ov-16 ELISA. Bivariate analyses by age group were performed with χ 2 test for categorical data. Where a cell value was below 5, Fisher’s exact test for two-way tables was applied. The criterion for significance was set at P < 0.05 based on a two-sided test. All statistical analyses were performed using SPSS v.22 (SPSS Inc., Chicago, Illinois, USA).
Results and discussion
A total of 140 houses and 544 study participants agreed to be part of this study. None of the 544 skin snip assessments for MF detection was found positive (data not shown). Blood samples on Whatman paper were collected and analyzed from 531 participants, as the samples from community # 16 were missed during the field work.
Based on the Ov-16 ELISA, the data obtained in the study of the 19 communities showed that the onchocerciasis seroprevalence was 7.9 %, mainly concentrated in rural settings (Table 2). To confirm this result, the positive samples were checked by a commercial test that yielded similar data (40 were positive, 1 was undetermined and 1 negative).
Table 3 shows the distribution of the onchocerciasis-seropositive individuals in the different surveyed communities. As indicated above, rural communities exhibited the highest number of seropositive individuals for onchocerciasis, with significant differences in relation to the urban ones. Among the rural setups, communities # 7, # 20 and # 14, had the highest seropositivity percentage (29.2, 26.9 and 23.8 %, respectively). The higher prevalence detected in rural communities emphasizes the problem of control strategies implementation in this kind of setting due to difficulties in access, cultural barriers and preference for traditional methods which has already been observed before . With respect to the urban settings, we did not find any positive case in communities # 3, # 6, # 8, # 9, # 10, # 12 and # 17, although communities # 2 and # 18 showed 15.2 and 14.3 % of seropositivity, respectively.
The seroprevalence by age group was also assessed. No positive samples were found in 10 year-old individuals or younger, while participants older than 50 years were the ones with the highest prevalence (χ2 = 33.762, df = 4, P < 0.001), being 19 % onchocerciasis positive by Ov-16-ELISA (Fig. 2). The percentage of individuals with an undetermined serology increased with age (Fig. 2). A sample was considered undetermined when its absorbance was on the pre-defined cut-off, 40 arbitrary units (Table 1). These undetermined results could correspond to individuals previously in contact with the filaria, which after effective treatment with ivermectin, were losing antibodies to Ov-16 to finally become seronegative.
In this paper we evaluated serologically (Ov-16-ELISA) the impact of control programmes on onchocerciasis carried out in Bioko Island, Equatorial Guinea. We observed a significant decrease in the disease prevalence after years of ivermectin administration; the decline (IgG4 antibody title) was less pronounced in rural communities and individuals aged 10 years and above. Previously published data by Mas et al.  showed a reduction in the prevalence and intensity in O. volvulus after 8 years of CDTI on Bioko Island; the authors selected rural communities, examined more than 1000 individuals by MF counts in skin-snips, and found out that the disease prevalence had decreased from 74.5 to 38.4 % in the period 1989–1998. The ivermectin distribution continued over time thanks to APOC, reaching coverages between 50 and 75 % in most endemic areas . In parallel, the demonstration of the elimination of the Bioko form S. yahense (larviciding with temephos, 2001–2005)  promoted a new epidemiological scenario with a sharp decline in parasite load. In such epidemiological situation, more sensitive and specific diagnosis tools, as genomic procedures (PCR) and/or recombinant antigens-serology would be needed in order to evaluate the potential interruption of filarial transmission in Bioko Island. The Ov-16 serology with IgG4-system [18, 19, 29] has been a major advance in the fight against onchocerciasis. It has been widely used for certification of the elimination of the disease in the Americas  and in some African regions [4, 24, 25]. The Ov-16 antigen exhibits an excellent performance for onchocerciasis diagnosis, although some cross-reactions with Mansonella ozzardi have been reported [19, 33]. Mansonella ozzardi is not present in Africa, so the handicap previously referred is not relevant to the present study. No such cross-reactivity with the other Mansonella spp. has been reported [16, 19]. Nevertheless, it an in-depth analysis of this aspect would be desirable considering that Mansonella perstans and Mansonella streptocerca are co-endemic with O. volvulus and highly prevalent in Africa . With respect to sensitivity, Ov-16-IgG4 assay works as an early and specific marker for O. volvulus infection . Interestingly, in the present work only positive IgG4 levels were detected in approximately 7.9 % of the tested population, in individuals aged 11 years and above and mainly settled in rural areas. The prevalence determined was significantly lower than that reported by Mas et al. . Nevertheless, it should be taken into account that Mas and co-workers used MF count that is much less sensitive than immunodiagnosis. Moreover, ivermectin administration has been continued over the last years.
In addition, it should be emphasized that according to the age, the younger population (5–10 year-old) did not present positive serology, meaning that no IgG4 antibodies were detected. This result is extremely important, in view of the fact that the absence of specific IgG4 antibodies highlights no parasite infection in children of Bioko Island, and therefore points to the possible interruption of parasite transmission in the region. Regarding the serologically positive individuals, it should be considered that according to Weil et al. , the seropositivity obtained in treated patients could be due to a progressive decline of IgG4 antibodies to Ov-16 over a period of years after apparent onchocerciasis curing. In this sense, the study carried out by Traoré et al.  showed the presumptive elimination of the vector of O. volvulus in the island since 2005. These results support the interruption of parasite transmission and human infection. Nevertheless, new entomological assessments to verify S. yahense elimination are desirable, including the study of other potential vectors which can become infected by the parasite and thus replace the old vector .
Our study has some limitations. First, the possibility of cross-reaction of Ov-16 ELISA test with some of Mansonella spp., highly prevalent in Africa, should be assessed in the future. Secondly, like other serological tests, the Ov-16 ELISA cannot differentiate recent from historical exposure. Moreover, it is currently not known how long the IgG4 antibody response to the Ov-16 antigen persists. Therefore, a larger number of samples would be necessary in order to define a more accurate seroprevalence in Bioko Island. Also, it would be required to increase the number of samples from children in each community to assess the possible interruption of transmission, since this will allow us to detect possible hot spots.
In the present work, a decline in onchocerciasis prevalence in humans was determined in Bioko Island after years of vector control measures and CDTI strategy. Nevertheless, the sample population was not large enough and only children above 5 years of age were tested. In the age group 5–10 year-old, none individual had IgG4 antibodies against recombinant Ov-16. Moreover, the Ov-16 seroprevalence increased with age, especially in rural settings, and no O. volvulus microfilariae were observed in skin-snips.
Further serological studies with larger human samples are needed, especially in children younger than 10 years, as recommended by recent updated WHO criteria (2016). Besides Ov-16 serology, the verification of S. yahense elimination in Bioko Island and the absence of parasite DNA in both human skin-snips and other potential simulid vectors are recommended to confirm the interruption of onchocerciasis transmission in the Bioko Island.
- ABST 2:
2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt
African programme for onchocerciasis control
Community-directed treatment with ivermectin
Enzyme linked immuno-sorbent assay
Onchocerca volvulus Ov-16 recombinant antigen with glutathione S-transferase (GST) tail
Immuno-globulin G, subclass G4
Mectizan donation programme
Ministry of Health in Equatorial Guinea and Social Welfare
Onchocerca volvulus recombinant 16-antigen
Onchocerciasis control programme
Onchocerca volvulus Ov-16 recombinant antigen with poly-histidine (His) tail
PBS plus 0.05 % Tween 20
Rapid epidemiological mapping of onchocerciasis
GST-tagged expression vector. It permits purification on Glutathione Sepharose and simultaneous site-specific cleavage of the recombinant protein
Maltose binding protein (MBP)-tagged expression vector. It permits the amylose resin-purification and cleaving with specific protease of the recombinant protein
World Health Organization
Bari A, Rahman SB. Onchocerciasis: a review of a filarial disease of significant importance for dermatologists and ophthalmologists. J Pak Asso Dermatol. 2007;17:32–45.
Nyerges AE. Development in the Guinea savanna. Science. 1987;238(4834):1637–8.
Sékétéli A, Adeoye G, Eyamba A, Nnoruka E, Drameh P, Amazigo UV, et al. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96 Suppl 1:15–28.
Lakwo TL, Garms R, Rubaale T, Katabarwa M, Walsh F, Habomugisha P, et al. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector Simulium neavei and 19 years of annual ivermectin treatments. Acta Trop. 2013;126:218–21.
Ngoumou P, Walsh JF. A manual for rapid epidemiological mapping of onchocerciaisis. TDR/TDE/ONCHOCERCIASIS/93.4. Geneva: World Health Organization; 1993.
Fobi G, Yameogo L, Noma M, Aholou Y, Koroma JB, Zouré HM, et al. Managing the fight against onchocerciasis in Africa: APOC Experience. PLoS Negl Trop Dis. 2015;9(5):e3542.
Mas J, Yumbe A, Solé N, Capote R, Cremades T. Prevalence, geographical distribution and clinical manifestations of onchocerciasis on the Island of Bioko (Equatorial Guinea). Trop Med Parasitol. 1995;46:13–8.
Mas J, Sima A, Untoria D, Post R, Limiñana C, Ncogo PR, et al. Onchocerciasis and its control in Equatorial Guinea (1919–1996). Res Rev Parasitol. 1996;56:147–55.
Mas J, Ascaso C, Escaramis G, Abellana R, Duran E, Sima A, et al. Reduction in the prevalence and intensity of infection in Onchocerca volvulus microfilariae according to ethnicity and community after 8 years of ivermectin treatment on the island of Bioko, Equatorial Guinea. Trop Med Int Health. 2006;11:1082–91.
Traoré S, Wilson MD, Sima A, Barro T, Diallo A, Aké A, et al. The elimination of the onchocerciasis vector from the Island of Bioko as a result of larviciding by the WHO African Programme for Onchocerciasis Control. Acta Trop. 2009;111:211–8.
WHO African Programme for Onchocerciasis Control: report of the CSA Advisory Group on Onchocerciasis Elimination. Ouagadougou, Burkina Faso: WHO/APOC; 2011.
Lloyd MM, Gilbert R, Taha NT, Weil GJ, Meite A, Kouakou IMM, et al. Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes. Acta Trop. 2015;146:114–8.
Bradley JE, Unnasch TR. Molecular approaches to the diagnosis of onchocerciasis. Adv Parasitol. 1996;37:57–106.
Harnett W, Bradley JE, Garate T. Molecular and immunodiagnosis of human filarial nematode infections. Parasitology. 1998;117(Suppl):59–71.
Alhassan A, Li Z, Poole CB, Carlow CK. Expanding the MDx toolbox for filarial diagnosis and surveillance. Trends Parasitol. 2015;31:391–400.
Weil GJ, Steel C, Liftis F, Li BW, Mearns G, Lobos E, et al. A rapid-format antibody card test for diagnosis of onchocerciasis. J Infect Dis. 2000;182:1796–9.
Lipner EM, Dembele N, Souleymane S, Alley WS, Prevots DR, Toe L, et al. Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. J Infect Dis. 2006;194:216–21.
Lobos E, Altmann M, Mengod G, Weiss N, Rudin W, Karam M. Identification of an Onchocerca volvulus cDNA encoding a low-molecular-weight antigen uniquely recognized by onchocerciasis patient sera. Mol Biochem Parasitol. 1990;39:135–45.
Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB. An immunogenic Onchocerca volvulus antigen: a specific and early marker of infection. Science. 1991;251:1603–5.
World Health Organization (WHO). Certification of Elimination of Human Onchocerciasis: Criteria and Procedures. Geneva: World Health Organization; 2001. http://apps.who.int/iris/bitstream/10665/66889/1/WHO_CDS_CPE_CEE_2001.18b.pdf. 28–29 September 2000.
Gonzalez RJ, Cruz-Ortiz N, Rizzo N, Richards J, Zea-Flores G, Domínguez A, et al. Successful interruption of transmission of Onchocerca volvulus in the Escuintla-Guatemala focus, Guatemala. PLoS Negl Trop Dis. 2009;3(3):e404.
Lovato R, Guevara A, Guderian R, Proaño R, Unnasch T, Criollo H, et al. Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution. PLoS Negl Trop Dis. 2014;8(5):e2821.
Rodríguez-Pérez MA, Fernández-Santos NA, Orozco-Algarra ME, Rodríguez-Atanacio JA, Domínguez-Vázquez A, Rodríguez-Morales KB, et al. Elimination of onchocerciasis from Mexico. PLoS Negl Trop Dis. 2015;9(7):e3922.
Katabarwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, Oguttu DW, et al. Transmission of onchocerciasis in Wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. J Parasitol Res. 2012;2012:748540.
Oguttu D, Byamukama E, Katholi CR, Habomugisha P, Nahabwe C, Ngabirano M, et al. Serosurveillance to monitor onchocerciasis elimination: the Ugandan experience. Am J Trop Med Hyg. 2014;90:339–45.
World Health Organization (WHO). Guidelines for Stopping Mass Drug. Administration and Verifying Elimination of Human Onchocerciasis: Criteria and Procedures. Geneva: World Health Organization; 2016. p. 37.
McCall PJ, Cheke RA, Wilson MD, Post RJ, Flook PK, Mank R, et al. Distribution of the Simulium damnosum complex on Bioko Island, Equatorial Guinea, and the potential for onchocerciasis elimination by vector eradication. Med Vet Entomol. 1998;12:267–75.
Tang TH, López-Vélez R, Lanza M, Shelley AJ, Rubio JM, Luz SL. Nested PCR to detect and distinguish the sympatric filarial species Onchocerca volvulus, Mansonella ozzardi and Mansonella perstans in the Amazon Region. Mem Inst Oswaldo Cruz. 2010;105:823–8.
Lindblade KA, Arana B, Zea-Flores G, Rizzo N, Porter CH, Dominguez A, et al. Elimination of Onchocerca volvulus transmission in the Santa Rosa focus of Guatemala. Am J Trop Med Hyg. 2007;77:334–41.
Brieger WR, Sommerfeld JU, Amazigo UV. CDI Network: the potential for community-directed interventions: Reaching underserved populations in Africa. Int Q Community Health Educ. 2015;35:295–316.
Tchuem Tchuente LA, Wanji S, Sima Nsue A, Zoure HGM. Informe sobre Trazado Integrado de Enfermedades Tropicales Descuidadas en Guinea Ecuatorial (oncocercosis, filariasis linfática, loiasis, esquistosomiasis y helmintiasis transmitida por contacto con el suelo). Malabo, Equatorial Guinea: Programa Africano para el Control de la Oncocercosis (APOC); 2008.
Richards Jr F, Rizzo N, Diaz Espinoza CE, Morales Monroy Z, Crovella Valdez CG, de Cabrera RM, et al. One hundred years after its discovery in Guatemala by Rodolfo Robles, Onchocerca volvulus transmission has been eliminated from the Central Endemic Zone. Am J Trop Med Hyg. 2015;93:1295–304.
Luz SL, Crainey JL, Shelley AJ, Rubio M. Outstanding insecurities concerning the use of an Ov-16-based ELISA in the Amazonia onchocerciasis focus. Mem Inst Oswaldo Cruz. 2014;109:506–8.
Onapa AW, Simonsen PE, Baehr I, Pedersen EM. Rapid assessment of the geographical distribution of Mansonella perstans infections in Uganda, by screening schoolchildren for microfilariae. Ann Trop Med Parasitol. 2005;99:383–93.
Garms R, Badu K, Owusu-Dabo E, Baffour-Awuah S, Adjei O, Debrah AY, et al. Assessments of the transmission of Onchocerca volvulus by Simulium sanctipauli in the Upper Denkyira District, Ghana, and the intermittent disappearance of the vector. Parasitol Res. 2015;114:1129–37.
We would like to thank the National Program for Control of Onchocerciasis and other Filariasis in Equatorial Guinea for supporting us to obtain the information on which this study is based. We are grateful to the study participants for volunteering to participate in the study and the data collectors for performing field work. Our gratitude to the Unit of Serological Diagnosis, Department of Parasitology, Centro Nacional de Microbiología, and the Spanish Red Cross for providing some control samples. Thanks are also due to Diana Gomez-Barroso, from the National Centre of Epidemiology (ISCIII) for her help with the mapping.
We would like to acknowledge the Spanish Agency of International Development Cooperation (AECID) and the Network of Biomedical Research on Tropical Diseases (RICET) for supporting this study RD12/0018/0001 and RD12/0018/0011, AESI (MPY1279/15) and Sarah Borrell Program for supporting Ana Hernandez contract.
Availability of data and materials
The data supporting the conclusions of this article are included within the article.
Conceived and designed the experiments: AHG, LM, MJP, ZH, RN, JN, PA, AB, TG. Performed the experiments: AHG, LM, ZH, TG. Analysed the data: AHG, LM, MJP, ZH, RN, JN, PA, AB, TG. Contributed reagents/materials/analysis tools: AHG, LM, MJP, ZH, PA, AB, TG. Wrote the paper: AHG, LM, MJP, ZH, PA, AB, TG. All authors read and approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
This study was approved by the ethical advisory boards of Institute of Health Carlos III in Spain (CEI PI 21_2014) and the Ministry of Health in Equatorial Guinea and Social Welfare (MINSABS). The study complied with current national and international regulations and standards for biomedical research in human subjects. The village and neighbourhood representatives were informed by an official letter from the MINSABS of the day of the visit and the scope of the study. Written informed consent was obtained from all patients prior to study inclusion. Anonymity was assured. A written statement was also included on the introductory part of the questionnaires in which further information concerning the purpose of the study and the confidentiality of the research information was given. Data were analyzed in anonymous form.
About this article
Cite this article
Hernández-González, A., Moya, L., Perteguer, M.J. et al. Evaluation of onchocerciasis seroprevalence in Bioko Island (Equatorial Guinea) after years of disease control programmes. Parasites Vectors 9, 509 (2016) doi:10.1186/s13071-016-1779-8
- Onchocerca volvulus
- Bioko Island
- Equatorial Guinea
- Ov-16/IgG4 ELISA